Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that its collaborator... studies. Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year. "The development of novel anti-obesity... manufactured. Based on the compound's prior use in humans for other medical disorders Compellis Pharmaceuticals believes it will be eliminating some of the development time required...

biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that its collaborator Pennington Biomedical Research Institute at Louisiana... in the first quarter of 2008 with an expected completion date in the second half of the year. "The development of novel anti-obesity therapies has been a focus of my research for 30... in humans for other medical disorders Compellis Pharmaceuticals believes it will be eliminating some of the development time required for new molecular entities. The result...

and may lead to weight loss Boston, Mass., October 27, 2008 Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics... with unproven compounds will not be an issue with CP404. The result is a focused clinical development process that may result in a faster time to market. About Compellis Pharmaceuticals..., Inc.Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity. The company reformulates FDA approved...

may lead to reduction in appetite and weight loss. Boston, Mass., December 5, 2006 Compellis Pharmaceuticals, a biopharmaceutical company developing novel mechanism-based... of the drawbacks typically associated with unproven compounds. The result will be a focused clinical development process that may result in a faster time to market. About Compellis... Pharmaceuticals, Inc. Compellis Pharmaceuticals is an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity. The company reformulates...

developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,435,407) by the U.S. Patent and Trademark... of the drawbacks typically associated with unproven compounds will not be an issue with CP404. The result is a focused clinical development process that may result in a faster time... to market. About Compellis Pharmaceuticals, Inc.Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment...